ArticleAntimicrobial agents and chemotherapy1997
Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice.
Article in Antimicrobial agents and chemotherapy, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 126 citations in OpenAlex.
- Bacteria-Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Nanoparticle carriers in the treatment of intracellular bacterial infections: Current approaches and challenges.International journal of pharmaceutics: X · 2026Review
- Liposome-Encapsulated Antibiotics for the Therapy of Mycobacterial Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Efficacy of Combined Rifampicin Formulations Delivered by the Pulmonary Route to Treat Tuberculosis in the Guinea Pig Model.Pharmaceutics · 2021Article
- Antituberculosis Targeted Drug Delivery as a Potential Future Treatment Approach.Antibiotics (Basel, Switzerland) · 2021Review
- Preclinical Evidence of Nanomedicine Formulation to TargetPathogens (Basel, Switzerland) · 2020Article
- Recent advances in the treatment of pathogenic infections using antibiotics and nano-drug delivery vehicles.Drug design, development and therapy · 2019Review
- Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.Current drug delivery · 2019Review
- Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies.Expert opinion on drug delivery · 2018Review
- Nanotechnology-Based Approach in Tuberculosis Treatment.Tuberculosis research and treatment · 2017Review
- Plasmid-encoding vasostatin inhibited the growth and metastasis of human hepatocellular carcinoma cells.Molecular and cellular biochemistry · 2014Article
- Novel technologies: A weapon against tuberculosis.Indian journal of pharmacology · 2010Article
- Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34-->Ala mutant.Journal of experimental & clinical cancer research : CR · 2008Article
- Formation of inhalable rifampicin-poly(L-lactide) microparticles by supercritical anti-solvent process.AAPS PharmSciTech · 2008Article
- Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis.Pharmaceutical research · 2001Article
- Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model.Pharmaceutical research · 2001Article
- Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice.Antimicrobial agents and chemotherapy · 1999Article
- Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages.Antimicrobial agents and chemotherapy · 1998Article
- Nanoparticle approaches against bacterial infections.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
- Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles.Signal transduction and targeted therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One recent promising development in the modification of drug formulations to improve chemotherapy is the use of a liposome-mediated drug delivery system. The efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes were evaluated by injecting liposomal drugs and free drugs into tuberculous mice twice a week for 6 weeks. Liposome-encapsulated drugs at and below therapeutic concentrations were more effective than free drugs against tuberculosis, as evaluated on the basis of CFUs detected, organomegaly, and histopathology. Furthermore, liposomal drugs had marginal hepatotoxicities as determined from the levels of total bilirubin and hepatic enzymes in serum. The elimination of mycobacteria from the liver and spleen was also higher with liposomal drugs than with free drugs. The encapsulation of antitubercular drugs in lung-specific stealth liposomes seems to be a promising therapeutic approach for the chemotherapy of tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.